Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

HIF-1α and HIF-2α Differently Regulate the Radiation Sensitivity of NSCLC Cells.

Moreno Roig E, Groot AJ, Yaromina A, Hendrickx TC, Barbeau LMO, Giuranno L, Dams G, Ient J, Olivo Pimentel V, van Gisbergen MW, Dubois LJ, Vooijs MA.

Cells. 2019 Jan 12;8(1). pii: E45. doi: 10.3390/cells8010045.

2.

Can Intestinal Phosphate Binding or Inhibition of Hydroxyapatite Growth in the Vascular Wall Halt the Progression of Established Aortic Calcification in Chronic Kidney Disease?

Neven E, Opdebeeck B, De Maré A, Bashir-Dar R, Dams G, Marynissen R, Behets GJ, Verhulst A, Riser BL, D'Haese PC.

Calcif Tissue Int. 2016 Nov;99(5):525-534. Epub 2016 Jul 26.

PMID:
27461215
3.

Disturbances in Bone Largely Predict Aortic Calcification in an Alternative Rat Model Developed to Study Both Vascular and Bone Pathology in Chronic Kidney Disease.

Neven E, Bashir-Dar R, Dams G, Behets GJ, Verhulst A, Elseviers M, D'Haese PC.

J Bone Miner Res. 2015 Dec;30(12):2313-24. doi: 10.1002/jbmr.2585. Epub 2015 Aug 3.

4.

A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats.

Neven E, De Schutter TM, Dams G, Gundlach K, Steppan S, Büchel J, Passlick-Deetjen J, D'Haese PC, Behets GJ.

PLoS One. 2014 Sep 17;9(9):e107067. doi: 10.1371/journal.pone.0107067. eCollection 2014.

5.

Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.

Behets GJ, Dams G, Damment SJ, Martin P, De Broe ME, D'Haese PC.

Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F61-7. doi: 10.1152/ajprenal.00219.2013. Epub 2013 Nov 6. Erratum in: Am J Physiol Renal Physiol. 2014 Mar 1;306(5):F568.

6.

An automated time-of-drug-addition assay to routinely determine the mode of action of HIV-1 inhibitors.

Van Loock M, Van den Eynde C, Hansen J, Geluykens P, Ivens T, Sauviller S, Bunkens L, Van Acker K, Nijs E, Dams G.

Assay Drug Dev Technol. 2013 Oct;11(8):489-500. doi: 10.1089/adt.2013.529.

PMID:
24144343
7.

Identification of HIV-1 reverse transcriptase inhibitors using a scintillation proximity assay.

Van Schoubroeck B, Van Loock M, Ivens T, Dehertogh P, Jochmans D, Dams G.

Methods Mol Biol. 2013;1030:19-24. doi: 10.1007/978-1-62703-484-5_3.

PMID:
23821257
8.

A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.

Smeulders L, Bunkens L, Vereycken I, Van Acker K, Holemans P, Gustin E, Van Loock M, Dams G.

Methods Mol Biol. 2013;1030:11-7. doi: 10.1007/978-1-62703-484-5_2.

PMID:
23821256
9.

A fluorescence-based high-throughput screening assay to identify HIV-1 inhibitors.

Geluykens P, Van Acker K, Vingerhoets J, Van den Eynde C, Van Loock M, Dams G.

Methods Mol Biol. 2013;1030:3-9. doi: 10.1007/978-1-62703-484-5_1.

PMID:
23821255
10.

Design, synthesis, and antiviral evaluation of purine-β-lactam and purine-aminopropanol hybrids.

D'hooghe M, Mollet K, De Vreese R, Jonckers TH, Dams G, De Kimpe N.

J Med Chem. 2012 Jun 14;55(11):5637-41. doi: 10.1021/jm300383k. Epub 2012 May 17.

PMID:
22519297
11.

MAPPIT as a high-throughput screening assay for modulators of protein-protein interactions in HIV and HCV.

Van Schoubroeck B, Van Acker K, Dams G, Jochmans D, Clayton R, Berke JM, Lievens S, Van der Heyden J, Tavernier J.

Methods Mol Biol. 2012;812:295-307. doi: 10.1007/978-1-61779-455-1_18.

PMID:
22218868
12.

A novel high-throughput cellular screening assay for the discovery of HIV-1 integrase inhibitors.

Van Loock M, Meersseman G, Van Acker K, Van Den Eynde C, Jochmans D, Van Schoubroeck B, Dams G, Heyndrickx L, Clayton RF.

J Virol Methods. 2012 Feb;179(2):396-401. doi: 10.1016/j.jviromet.2011.11.029. Epub 2011 Dec 7.

PMID:
22172974
13.

Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.

Neven E, Dams G, Postnov A, Chen B, De Clerck N, De Broe ME, D'Haese PC, Persy V.

Nephrol Dial Transplant. 2009 Jun;24(6):1790-9. doi: 10.1093/ndt/gfn737. Epub 2009 Jan 14.

PMID:
19144999
14.

A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.

Dams G, Van Acker K, Gustin E, Vereycken I, Bunkens L, Holemans P, Smeulders L, Clayton R, Ohagen A, Hertogs K.

J Biomol Screen. 2007 Sep;12(6):865-74. Epub 2007 Jul 20.

PMID:
17644771
15.

Role of dietary phosphorus and degree of uremia in the development of renal bone disease in rats.

Oste L, Behets GJ, Dams G, Bervoets AR, Marynissen RL, Geryl H, Van Hoof VO, De Broe ME, D'Haese PC.

Ren Fail. 2007;29(1):1-12.

PMID:
17365904
16.

High-resolution X-ray microtomography is a sensitive method to detect vascular calcification in living rats with chronic renal failure.

Persy V, Postnov A, Neven E, Dams G, De Broe M, D'Haese P, De Clerck N.

Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2110-6. Epub 2006 Jul 13.

PMID:
16840714
17.

Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.

Bervoets AR, Oste L, Behets GJ, Dams G, Blust R, Marynissen R, Geryl H, De Broe ME, D'Haese PC.

Bone. 2006 Jun;38(6):803-10. Epub 2006 Jan 18.

PMID:
16412714
18.

Effects of efficient phosphate binding on bone in chronic renal failure rats.

Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC.

Ren Fail. 2005;27(4):475-84.

PMID:
16060138
19.

Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.

Ivens T, Van den Eynde C, Van Acker K, Nijs E, Dams G, Bettens E, Ohagen A, Pauwels R, Hertogs K.

J Virol Methods. 2005 Oct;129(1):56-63.

PMID:
15961169
20.

Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats.

Oste L, Bervoets AR, Behets GJ, Dams G, Marijnissen RL, Geryl H, Lamberts LV, Verberckmoes SC, Van Hoof VO, De Broe ME, D'Haese PC.

Kidney Int. 2005 Mar;67(3):920-30.

21.

Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?

Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D'Haese PC.

J Am Soc Nephrol. 2004 Aug;15(8):2219-28.

22.

Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis.

Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, Couttenye MM, De Broe ME, D'Haese PC.

Nephrol Dial Transplant. 2003 Jun;18(6):1159-66.

PMID:
12748350
23.

Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients.

Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D'Haese PC.

Am J Kidney Dis. 2003 May;41(5):997-1007.

PMID:
12722034
24.

Dose-dependent effects of strontium on bone of chronic renal failure rats.

Schrooten I, Behets GJ, Cabrera WE, Vercauteren SR, Lamberts LV, Verberckmoes SC, Bervoets AJ, Dams G, Goodman WG, De Broe ME, D'Haese PC.

Kidney Int. 2003 Mar;63(3):927-35.

25.

Prevalence of Candida dubliniensis isolates in a yeast stock collection.

Odds FC, Van Nuffel L, Dams G.

J Clin Microbiol. 1998 Oct;36(10):2869-73.

26.
27.

Oxygen as limiting nutrient for growth of Cryptococcus neoformans.

Odds FC, De Backer T, Dams G, Vranckx L, Woestenborghs F.

J Clin Microbiol. 1995 Apr;33(4):995-7.

Supplemental Content

Support Center